Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation
BackgroundThe use of 5-hydroxytryptamine-3 receptor antagonists (5HT3RA) has long been considered the standard regimen for preventing chemotherapy-induced nausea and vomiting (CINV) prior to hematopoietic stem cell transplantation (HSCT). However, their therapeutic outcomes have been unsatisfactory....
Main Authors: | Hang Zhang, Qiang Zeng, Tian Dong, Xinchuan Chen, Pu Kuang, Jian Li, Qiuhui Wu, Ting Liu, Ting Niu, Zhigang Liu, Jie Ji |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1280336/full |
Similar Items
-
Concomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis
by: Miho Takemura, et al.
Published: (2022-08-01) -
Phase II study of pregabalin for the prevention of chemotherapy induced nausea and vomiting
by: Carla Santos Rossi Paniquar, et al.
Published: (2024-03-01) -
Fosaprepitant: current options to prevent chemotherapy-induced nausea and vomiting: A review
by: Nikolai A. Ognerubov
Published: (2023-02-01) -
Effect of Selective 5-Hydroxytryptamine-3 Receptor and Neurokinin-1 Receptor Antagonists on Hemodynamic Changes and Arrhythmogenic Potential in Patients Receiving Chemotherapy: A Retrospective, Observational Study
by: Utku Burak Bozbulut, et al.
Published: (2024-02-01) -
Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
by: Laurent Zelek, et al.
Published: (2023-08-01)